@Article{096504016X14537290676865,
AUTHOR = {Vanita Noronha, Kumar Prabhash, Amit Joshi, Vijay Maruti Patil, Sanjay Talole, Dipti Nakti, Arvind Sahu, Srushti Shah, Sarbani Ghosh-Laskar, Prachi S. Patil, Shaesta A. Mehta, Nirmala Jambhekar, Abhishek Mahajan, Nilendu Purandare},
TITLE = {Clinical Outcome in Definitive Concurrent Chemoradiation  With Weekly Paclitaxel and Carboplatin for Locally Advanced  Esophageal and Junctional Cancer},
JOURNAL = {Oncology Research},
VOLUME = {23},
YEAR = {2015},
NUMBER = {4},
PAGES = {183--195},
URL = {http://www.techscience.com/or/v23n4/57555},
ISSN = {1555-3906},
ABSTRACT = {There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/
m2
 and carboplatin AUC 2 with radical definitive RT for locally advanced esophageal/GEJ cancer. Between 
February 2011 and July 2014, 179 patients were included. The median age was 54 years. Ninety-two percent 
of patients had squamous histology. Mean RT dose was 58.7 Gy in 32 fractions over 53 days, with mean of 
six chemotherapy cycles. Fifty-six percent of patients developed ³grade 3 acute toxicities, commonly febrile 
neutropenia (12%) and infection (11%); ³grade 3 laboratory abnormalities included hyponatremia (38%), leukopenia (49%), neutropenia (27%), and anemia (16%). Twelve percent of patients developed ³grade 3 chronic 
toxicity. Fatal toxicities included six during CRT, eight within 30 days of completing CRT, and three chronic. 
Radiologic response was 49% (CR 5.6%, PR 43%). Follow-up endoscopy showed remission in 53% and residual disease in 14%. At a median follow-up of 28 months, median PFS was 11 months (95% CI: 8–13.9), median 
OS was 19 months (95% CI: 15.4–22.6), and estimated 1-year, 2-year, and 3-year survivals were 70%, 47%, 
and 39%, respectively. Weekly paclitaxel–carboplatin concurrently with definitive RT is efficacious with manageable toxicity. [The trial was registered with the Clinical Trials Registry-India (CTRI), registration number: 
CTRI/2014/07/004776.]},
DOI = {10.3727/096504016X14537290676865}
}